SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:prod.swepub.kib.ki.se:150845797"
 

Search: id:"swepub:oai:prod.swepub.kib.ki.se:150845797" > Comparison of outco...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Raj, K (author)

Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2022-09-28
  • Springer Science and Business Media LLC,2022

Numbers

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:150845797
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:150845797URI
  • https://doi.org/10.1038/s41408-022-00729-yDOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. The median age at transplant with MSD was 58 and 61 years for HD. The median time to neutrophil engraftment was longer for HD being 20 vs 16 days for MSD (p < 0.001). Two-year overall survival (OS) and PFS (progression free survival) with MSD were significantly better at 58% compared with 50%, p ≤ 0.001, and 51% vs 47%, p = 0.029, with a HD. Relapse at 2 years was lower with a HD 23% than with MSD 29% (p = 0.016). Non relapse mortality (NRM) was higher with HD in the first 6 months post-transplant [HR 2.59 (1.5–4.48) p < 0.001] and was also higher at 2 years being 30% for HD and 20% for MSD, p ≤ 0.001. The incidence of acute GVHD grade II-IV and III–IV at 100 days was comparable for MSD and HD, however, chronic GVHD at 2 years was significantly higher with MSD being 44% vs 32% for HD (p < 0.001). After multivariable analysis, OS and primary graft failure were significantly worse for HD particularly before 6 months [HR 1.93(1.24–3.0)], and HR [3.5(1.5–8.1)]. The median age of HD 37 (IQR 30–47) years was significantly lower than sibling donors 56 (IQR 49–62 years) p < 0.001. However, there was no effect on NRM, relapse or PFS. This data set suggests that a MSD donor remains the preferred choice in MDS over a haplo donor. Transplants with haploidentical donors result in satisfactory long-term outcome, justifying it’s use when no better donor is available.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Eikema, DJ (author)
  • Sheth, V (author)
  • Koster, L (author)
  • de Wreede, LC (author)
  • Blaise, D (author)
  • Di Grazia, C (author)
  • Koc, Y (author)
  • Potter, V (author)
  • Chevallier, P (author)
  • Lopez-Corral, L (author)
  • Wu, DP (author)
  • Mielke, SKarolinska Institutet (author)
  • Maertens, J (author)
  • Meijer, E (author)
  • Huynh, A (author)
  • Passweg, J (author)
  • Luft, T (author)
  • Perez-Simon, JA (author)
  • Ciceri, F (author)
  • Piekarska, A (author)
  • Ozsan, GH (author)
  • Kroger, N (author)
  • Robin, M (author)
  • Yakoub-Agha, I (author)
  • Karolinska Institutet (creator_code:org_t)

Related titles

  • In:Blood cancer journal: Springer Science and Business Media LLC12:9, s. 140-2044-5385

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view